Blepharoptosis After Intravitreal Anti-VEGF Injections: A Prospective Study.
Irene Bermudez-Castellanos, Augusto Cruz Velasco, Denny Marcos Garcia...
https://pubmed.ncbi.nlm.nih.gov/41022034/Actively Recruiting
Led by Abdulkadir Küçük · Updated on 2026-11-02
60
Participants Needed
1
Research Sites
1 weeks
Total Duration
Researchers are observing the potential development of blepharoptosis, or eyelid drooping, in patients receiving repeated intravitreal anti-VEGF injections for retinal diseases such as neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. This study enrolls 60 patients starting treatment in one eye only, using the untreated eye as a control to compare changes over six months. The study is prospective, single-center, and non-interventional, aiming to assess eyelid position and function after these injections. Participants receive anti-VEGF injections like ranibizumab, aflibercept, or bevacizumab under routine sterile conditions with topical anesthesia and an eyelid speculum to hold the eyelids open. The treating retina specialist decides the agent, injection interval, and number of injections based on clinical need. The study measures eyelid parameters including margin reflex distance-1 MRD-1, margin reflex distance-2 MRD-2, and levator function at baseline and at months 1, 3, and 6 in both eyes. During the study, participants attend scheduled visits where the same examiner assesses eyelid measurements for both eyes. Researchers record the cumulative number of injections and speculum uses at each visit. The primary outcome is the difference in MRD-1 change between treated and untreated eyes at 6 months. Secondary outcomes include differences in MRD-2 and levator function, incidence of clinically significant blepharoptosis, and correlations between injection number and eyelid changes. The study lasts six months, with safety and adherence monitored through consistent follow-up assessments.
CONDITIONS
Blepharoptosis After Repeated Intravitreal Anti-VEGF Injections: A Prospective Study
A
Abdulkadir Küçük, MD
F
Fatih Çoban, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Abdulkadir Küçük
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 months
Participants receive intravitreal anti-VEGF injections in one eye as part of routine care. Eyelid position and function are measured in both eyes at baseline and at months 1, 3, and 6 to monitor changes.
4 visits (baseline, 1, 3, and 6 months)
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Irene Bermudez-Castellanos, Augusto Cruz Velasco, Denny Marcos Garcia...
https://pubmed.ncbi.nlm.nih.gov/41022034/Efraim Berco, Michael Ostrovsky, Obinna Esomchukwu...
https://pubmed.ncbi.nlm.nih.gov/39945841/Abdulkadir Küçük
Lead Sponsor